KRAS and lung carcinoma: In addition, MEK inhibitors in combination with ICIs led to an increase in tumor-infiltrating T cells and a decrease in the percentage of MDSCs, which in turn significantly inhibited tumor growth in TP53/KRAS-driven lung cancer mouse models 137.